S15 Ep32: Lisaftoclax Plus Azacitidine May Make New Inroads in Higher-Risk MDS Management: With Guillermo Garcia-Manero, MD
In today’s episode, the discussion features Guillermo Garcia-Manero, MD, who reviewed the clinical rationale for targeting BCL-2 in higher-risk myelodysplastic syndrome (MDS) and outlined the phase 3 GLORA-4 trial (NCT06641414) evaluating lisaftoclax (APG-2575) plus azacitidine (Vidaza) in this population. Dr Garcia-Manero is the chair ad interim in the Department of Leukemia in the Division of Cancer Medicine, as well as leader of the MDS/AML Moon Shot Program, at The University of Texas MD Anderson Cancer Center in Houston.
In the exclusive interview, Dr Garcia-Manero contextualized…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.